What am I missing as the PPS has not been anywhere near $1.00. I came across this about 10 minutes ago so I may just be too new and can't see something thats obvious and right in front of. $9.94 +1.92 (+23.94%)
MINNEAPOLIS, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, announced today it received an extension of 180 calendar days from the Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Bid Price Requirement”), following the expiration of the initial 180 calendar days period to regain compliance on November 28, 2022.
As a result of the extension, the Company now has until May 29, 2023 to regain compliance with the Bid Price Requirement. If at any time before May 29, 2023, the bid price of the Company’s common shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it has achieved compliance with the Bid Price Requirement.
This current notification from Nasdaq has no immediate effect on the listing or trading of the Company’s shares, which will continue to trade on the Nasdaq Capital Market under the symbol “NUWE”.
MINNEAPOLIS, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, announced today it received an extension of 180 calendar days from the Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Bid Price Requirement”), following the expiration of the initial 180 calendar days period to regain compliance on November 28, 2022.
As a result of the extension, the Company now has until May 29, 2023 to regain compliance with the Bid Price Requirement. If at any time before May 29, 2023, the bid price of the Company’s common shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it has achieved compliance with the Bid Price Requirement.
This current notification from Nasdaq has no immediate effect on the listing or trading of the Company’s shares, which will continue to trade on the Nasdaq Capital Market under the symbol “NUWE”.
Recent NUWE News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/22/2026 09:09:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:01:48 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 03:30:04 PM
- Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label • GlobeNewswire Inc. • 05/14/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 08:04:46 PM
- Nuwellis, Inc. Announces First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026 • GlobeNewswire Inc. • 05/05/2026 12:00:00 PM
- Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual Meeting • GlobeNewswire Inc. • 04/29/2026 12:30:00 PM
- Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter Technology • GlobeNewswire Inc. • 04/28/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 09:00:23 PM
- Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Nuwellis Announces Aquadex Software Update • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum • GlobeNewswire Inc. • 04/16/2026 12:30:00 PM
- Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services • GlobeNewswire Inc. • 04/09/2026 12:30:00 PM
- Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory • GlobeNewswire Inc. • 04/07/2026 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 08:30:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 09:01:21 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:45:27 PM
- Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone • GlobeNewswire Inc. • 03/31/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 08:55:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 01:13:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 08:02:58 PM
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/10/2026 12:15:00 PM
